(18)F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study

PURPOSE: (18)F-Fluorodeoxyglucose positron emission tomography (FDG PET) has been used to assess metabolic response several months after stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer. However, whether a metabolic response can be observed already during treatment an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiegman, Erwin M., Pruim, Jan, Ubbels, Jan F., Groen, Harry J. M., Langendijk, Johannes A., Widder, Joachim
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094529/
https://www.ncbi.nlm.nih.gov/pubmed/21210108
http://dx.doi.org/10.1007/s00259-010-1706-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094529/
https://www.ncbi.nlm.nih.gov/pubmed/21210108
http://dx.doi.org/10.1007/s00259-010-1706-8

Ejemplares similares